Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans

Abstract Background Respiratory syncytial virus (RSV) causes high morbidity, with mortality rates approaching or exceeding that of influenza in adult and infant patient populations, respectively. Lumicitabine (ALS-008176 or JNJ-64041575) is an oral nucleoside analogue prodrug in clinical development...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2019-02, Vol.74 (2), p.442-452
Hauptverfasser:	Patel, Kashyap, Kirkpatrick, Carl M, Nieforth, Keith A, Chanda, Sushmita, Zhang, Qingling, McClure, Matthew, Fry, John, Symons, Julian A, Blatt, Lawrence M, Beigelman, Leo, DeVincenzo, John P, Huntjens, Dymphy R, Smith, Patrick F
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiviral Agents - blood Antiviral Agents - pharmacokinetics Antiviral Agents - therapeutic use Deoxycytidine - analogs & derivatives Deoxycytidine - blood Deoxycytidine - pharmacokinetics Deoxycytidine - therapeutic use Double-Blind Method Healthy Volunteers Humans Models, Theoretical Nasopharynx - virology Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus, Human - drug effects Respiratory Syncytial Virus, Human - physiology Viral Load - drug effects Virus Replication - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!